Acomplia (rimonabant) has not been licensed in the UK for smoking cessation. Whilst during clinical studies the drug clearly demonstrated a reduced craving for nicotine in patients the drug has only at the moment been approved as an obesity treatment. As this is a prescription medication we strongly advise that you seek to have a face to face consultation with your doctor in the first instance. Our service should not be interpreted as being a replacement to the treatment advice your doctor can provide.
How does Acomplia work?
Acomplia works on the so called endocannabinoid system, which is a system in the brain that affects energy balance, glucose and lipid metabolism and body weight. The result is that patients will experience the feeling of being full easier thus wanting to eat less than normally. This has been proven to significantly help obese patients achieve a weight loss if used in conjunction with a calorie reduced diet and exercise.
Undesirable effects of Acomplia
Acomplia has been studied in approximately 2500 patients who suffered from obesity or overweight to study any side effects. The studies showed that 15.7% experienced side effects the most common being nausea, mood alteration with depressive symptoms, depressive disorders, anxiety and dizziness. Depressive disorders were reported in 3.2% of patients and were usually mild or moderate in severity.
Contraindications
Acomplia should be used with caution in patients with the following conditions:
Moderate renal impairment
Aged over 75 years
Patients with epilepsy
Patients using potent CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir, telithromycin, clarithromycin, nefazodone)
Rare hereditary problems of galactose intolerance
Acomplia should not be used in patients with the following conditions:
Severe renal impairment
In patients with uncontrolled serious psychiatric illness such as a major depression.
Patients who had a cardiovascular event (myocardial infarction, stroke, etc.) less than 6 months ago
Patients who are breastfeeding
Patients who are pregnant
Indications for use
Acomplia is only licensed for weight control in patients with a BMI (Body Mass Index) above 30 or Patients with a BMI above 27 with associated risk factor(s), such as type 2 diabetes or dyslipidaemia.
Patients should take one 20mg tablet every morning with breakfast
Other weight loss options :
Acomplia
Rimonabant
Weight loss
Source:-www.onlineclinic.co.uk
No comments:
Post a Comment